

Please type a plus sign (+) inside this box ? ☐

PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete If Known		
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (use as many sheets as necessary)						
Sheet 4 of 8				Attorney Docket Number 795-A03-004		
U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
B	EA	2001/0029351	A1	Falotico et al.	10-11-2001	
	EB	2002/0016625	A1	Falotico et al.	02-07-2002	
	EC	2002/0013335	A1	Azrola et al.	01-31-2002	
	ED	2002/0007215	A1	Falotico et al.	01-17-2002	
	EE	2002/0007214	A1	Falotico et al.	01-17-2002	
	EF	2002/0007213	A1	Falotico et al.	01-17-2002	
	EG	2002/0005206	A1	Falotico et al.	01-17-2002	
B	EH	2003/0086957	A1	Huges	05-08-2003	
OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>6</sup>
B	FA	PEKKA HAYRY, Article " Genomics of Vascular Injury a Platform for Rational Drug Design" Internet Site Location, <a href="http://www.biohelsinkiconf.com/download/hayry-biotechelsinkio3.pdf">http://www.biohelsinkiconf.com/download/hayry-biotechelsinkio3.pdf</a>				
Examiner <i>[Signature]</i>				Date Considered 9/30/04		

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Please type a plus sign (+) inside this box ? ☐

PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

-Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b> (use as many sheets as necessary)				Complete If Known		
				Application Number		
				Filing Date		
				First Named Inventor		
				Group Art Unit		
				Examiner Name		
Sheet	2	of	8	Attorney Docket Number		
U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AW	5,688,824		Williams	11-18-1997	
	AX	5,728,710		Luengo	03-17-1998	
	AY	5,837,313		Ding et al.	11-17-1998	
	AZ	5,891,507		Jayaraman	04-06-1998	
	BA	5,997,468		Wolff et al.	12-07-1999	
	BB	6,046,328		Schonharting et al.	04-04-2000	
	BC	6,051,596		Badger	04-18-2000	
	BD	6,071,305		Brown et al.	06-06-2000	
	BE	6,129,705		Grantz	10-10-2000	
	BF	6,143,037		Goldstein et al.	11-07-2000	
	BG	6,153,252		Hossainy et al.	11-28-2000	
	BH	6,197,781		Guitard et al.	03-06-2001	
	BI	6,203,551		Wu	03-20-2001	
	BJ	6,231,600		Zhong	05-15-2001	
	BK	6,238,430		Klumb et al.	05-29-2001	
	BL	6,239,102		Tiemessen	05-29-2001	
	BM	6,239,124		Zenke et al.	05-29-2001	
	BN	6,245,104		Alt	06-12-2001	
	BO	6,248,127		Shah et al.	06-19-2001	
BP	6,251,136		Guruwaiya et al.	06-26-2001		
BQ	6,254,634		Anderson et al.	07-03-2001		
Examiner				Date Considered 7/30/04		

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Please type a plus sign (+) inside this box ? ☐

PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b> (use as many sheets as necessary)				Complete If Known	
				Application Number	
				Filing Date	
				First Named Inventor <b>S. Jayaraman</b>	
				Group Art Unit	
				Examiner Name	
Sheet	1	of	8	Attorney Docket Number <b>795-A03-004</b>	

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	3,903,071		Holmes	09-02-1975	
	AB	4,650,803		Stella et al.	03-17-1987	
	AC	5,100,899		Calne	03-31-1992	
	AD	5,212,155		Calne	05-18-1993	
	AE	5,221,740		Hughes	06-22-1993	
	AF	5,282,785		Shapland et al.	02-01-1994	
	AG	5,283,257		Gregory et al.	02-01-1994	
	AH	5,286,254		Shapland et al.	02-15-1994	
	AI	5,286,731		Caufield et al.	02-15-1994	
	AJ	5,288,711		Mitchell et al.	02-22-1994	
	AK	5,308,847		Calne	05-03-1994	
	AL	5,318,895		Kahn et al.	06-07-1994	
	AM	5,403,833		Calne	04-04-1995	
	AN	5,457,113		Cullinan et al.	10-10-1995	
	AO	5,461,058		Calne	10-24-1995	
	AP	5,496,832		Armstrong	03-05-1996	
	AQ	5,508,397		Or et al.	04-16-1996	
	AR	5,516,781		Morris et al.	05-14-1996	
AS	5,519,042		Morris et al.	05-21-1996		
AT	5,624,946		Williams	04-29-1997		
AU	5,646,160		Morris et al.	07-08-1997		
AV	5,674,732		Nishida et al.	10-07-1997		
Examiner				Date Considered <b>9/30/04</b>		

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Application Number		
			Filing Date		
			First Named Inventor	S. JAYARAMAN	
			Group Art Unit		
			Examiner Name		
Sheet	5	of	8	Attorney Docket Number	795-A03-004

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>2</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issuu number(s), publisher, city and/or country where published	T <sup>2</sup>
B	FB	D. BUNJES, C. HARDT, M. WILLINGHOFF and, H. WAGNER, CYCLOSPORIN A MEDIATES IMMUNOSUPPRESSION OF PRIMARY CYTOTOXIC T CELL RESPONSES BY IMPAIRING THE RELEASE OF INTERLEUKIN 1 AND INTERLEUKIN 2, J. IMMUNOL. 1981, 11:657-661.	
	FC	J. DIJOSEPH, E. FLUHLER, J. ARMSTRONG, M. SHARR, and S. SEHGAL, THERAPEUTIC BLOOD LEVELS OF SIROLIMUS (RAPAMYCIN) IN THE ALLOGRAFTED RAT, TRANSPLANTATION 1996, 62:1109-1112.	
	FD	B. HAUSEN, K. BOEKE, G. BERRY, I. BEGARRA, L. BENET, U. CHRISTIANS and R. MORRIS, COADMINISTRATION OF NEORAL AND THE NOVEL RAPAMYCIN ANALOG, SDZ RAD, TO RAT LUNG ALLOGRAFT RECIPIENTS, TRANSPLANTATION 1999, 67:956-962.	
	FE	L. TURKA, J. DAYTON, G. SINCLAIR, C. THOMPSON, and B. MITCHELL, GUANINE RIBONUCLEOTIDE DEPLETION INHIBITS T CELL ACTIVATION, J. Clin. Invest. 1991, 87:940-948.	
	FF	W. SCHULER, R. SEDRANI, S. COTTENS, B. HABERLIN, M. SCHULZ, H. SCHUURMAN, G. ZENKER, H. ZERWES, and M. SCHREIBER, SDZ RAD, A NEW RAPAMYCIN DERIVATIVE, TRANSPLANTATION 1997, 64:36-42.	
	FG	H. SCHUURMAN, J. RINGERS, W. SCHULER, W. SLINGERLAND and M. JONKER, ORAL EFFICACY OF THE MACROLIDE IMMUNOSUPPRESSANT SDZ RAD AND OF CYCLOSPORINE MICROEMULSION IN CYNOMOLGUS MONKEY KIDNEY ALLOTRANSPLANTATION, TRANSPLANTATION 2000, 69:737-742.	
	FH	J. SOUSA, A. ABIZAID, A. ABIZAID, F. FERES, I. PINTO, A. SEIXAS, R. STAICO, L. MATTOS, A. SOUSA, R. FALOTICO, J. JAEGER, J. POPMA, P. SERRUYS, M. COSTA, LACK OF NEOINTIMAL PROLIFERATION AFTER IMPLANTATION OF SIROLIMUS-COATED STENTS IN HUMAN CORONARY ARTERIES, CIRCULATION 2000, 102:r54-r57.	
	FI	C. GREGORY, S. KATZNELSON, S. GRIFFEY, A. KYLES and E. BERRYMAN, FLUVASTATIN IN COMBINATION WITH RAD SIGNICANTLY REDUCES GRAFT VASCULAR DISEASE IN RAT CARDIAC ALLOGRAFTS, CIRCULATION 2001, 72:989-993.	
	FJ	R. MORRIS, IMMUNOPHARMACOLOGY OF NEW XENOBIOTIC IMMUNOSUPPRESSIVE MOLECULES, SEMINARS IN NEPHROLOGY 1992, 12:304-314.	
	FK	J. MEHILLI, A. KASTRATI, W. KOCH, C. BOTTIGER, N. VON BECKERATH, A. SCHOMIG, RELATION BETWEEN TUMOR NECROSIS FACTOR (TNF) GENE POLYMORPHISMS AND THROMBOTIC EVENTS AND RESTENOSIS IN PATIENTS WITH CORONARY STENTING, ABSTRACT FROM ACCIS 2000 MEETING, 13A.	
B	FL	R. KNIGHT, M. FERRARESSO, F. SERINO, S. KATZ, R. LEWIS, AND B.D. KAHAN, LOW-DOSE RAPAMYCIN POTENTIATES THE EFFECTS OF SUBTHERAPEUTIC DOSES OF CYCLOSPORINE TO PROLONG RENAL ALLOGRAFT SURVIVAL IN THE MONGREL CANINE MODEL, TRANSPLANTATION 1993, 55:947-949.	

Examiner Signature		Date Considered	9/30/04
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	
				Filing Date	
				First Named Inventor S. JAYARAMAN	
				Group Art Unit	
				Examiner Name	
Sheet	6	of	8	Attorney Docket Number 795-A03-004	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
B P	FM	H SCHUURMAN, S COTTENS, S FUCHS, J JOERGENSEN, T MEERLOO, R SEDRANI, M TANNER, G ZENKE and W SCHULER, SDZ RAD, A NEW RAPAMYCIN DERIVATIVE, TRANSPLANTATION 1997, 64:32-35.	
	FN	B KAHAN, M MURGIA, J SLATION, and K NAPOLI, POTENTIAL APPLICATIONS OF THERAPEUTIC DRUG MONITORING OF SIROLIMUS IMMUNOSUPPRESSION IN CLINICAL RENAL TRANSPLANTATION, THERAPEUTIC DRUG MONITORING 1995, 17:672-675.	
	FO	R YATSCOFF, P WANG, K CHAN, D HICKS and J ZIMMERMAN, RAPAMYCIN: DISTRIBUTION, PHARMACOKINETICS, AND THERAPEUTIC RANGE INVESTIGATIONS, THERAPEUTIC DRUG MONITORING 1995, 17:666-671.	
	FP	H.U. SCHORLEMMER, F.R. SEILER, and R.R. BARTLETT, PROLONGATION OF ALLOGENEIC TRANSPLANTATION SKIN GRAFTS AND INDUCTION OF TOLERANCE BY LEFLUNOMIDE, A NEW IMMUNOSUPPRESSIVE ISOXAZOL DERIVATIVE, TRANSPLANTATIONS PROCEEDINGS 1993, 25:753-767.	
	FQ	D BRANISTEANU, C MATHIEU, R BOUILLON, SYNERGISM BETWEEN SIROLIMUS AND 1,25 DIHYDROXYVITAMIN D, IN VITRO AND IN VIVO, JOURNAL OF NEUROIMMUNOLOGY 1979, 79:138-147.	
	FR	B KAHAN, EFFICACY OF SIROLIMUS COMPARED WITH AZATHIOPRINE FOR REDUCTION OF ACUTE RENAL ALLOGRAFT REJECTION: A RANDOMISED MULTICENTRE STUDY, LANCET 2000, 356:194-202.	
	FS	B KLUGHERZ, G LLANOS, W LIEUALLEN, G KOPLA, G PAPANDREOU, P NARAYAN, T LEVENGOOD, B SASSEEN, S ADELMAN, R FALOTICO, R WILENEIR, STENT-BASED DELIVERY OF SIROLIMUS FOR THE PREVENTION OF RESTENOSIS, ABSTRACT FROM ACCIS 2000 MEETING.	
	FT	R SAUNDERS, M METCALFE, M NICHOLSON, RAPAMYCIN IN TRANSPLANTATION: A REVIEW OF EVIDENCE, KIDNEY INTERNATIONAL 2001, 59:3-16.	
	FU	R YATSCOFF, D LeGATT, and N KNETEMAN, THERAPEUTIC MONITORING OF RAPAMYCIN: A NEW IMMUNOSUPPRESSIVE DRUG, THERAPEUTIC DRUG MONITORING 1993, 15:478-482.	
	FV	S STEPKOWSKI, K NAPOLI, M WANG, X QU, T CHOU, and B KAHAN, EFFECTS OF THE PHARMACOKINETIC INTERACTION BETWEEN ORALLY ADMINISTERED SIROLIMUS AND CYCLOSPORINE ON THE SYNERGISTIC PROLONGATION OF HEART ALLOGRAFT SURVIVAL IN RATS, TRANSPLANTATION 1996, 62:986-994.	
B P	FW	B. HAUSEN, J. GUMMERT, G.J. BERRY, U. CHRISTIANS, N. SERKOVA, T. IKONEN, L. HOOK, F. LEGAY, W. SCHULER, M.H. SCHREIER, and R.E. MORRIS, PREVENTION OF ACUTE ALLOGRAFT REJECTION IN NONHUMAN PRIMATE LUNG TRANSPLANT RECIPIENTS, TRANSPLANTATION 2000, 69:468-496.	

Examiner Signature		Date Considered	9/30/04
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449B/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number			
		Filing Date			
		First Named Inventor	S. JAYARAMAN		
		Group Art Unit			
		Examiner Name			
Sheet	7	of	8	Attorney Docket Number	795-A03-004

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>2</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
B	FX	S SEHGAL, RAPAMUNE (SIROLIMUS, RAPAMYCIN): AN OVERVIEW AND MECHANISM OF ACTION, THERAPEUTIC DRUG MONITORING 1995, 17:660-665.	
	FY	R MORRIS, MECHANISMS OF ACTION OF NEW IMMUNOSUPPRESSIVE DRUGS, THERAPEUTIC DRUG MONITORING 1995, 17:564-569.	
	FZ	P KELLY, S GRUBER, F BEHBOD, and B KAHAN, SIROLIMUS, A NEW, POTENT IMMUNOSUPPRESSIVE AGENT, PHARMACOTHERAPY 1997, 17:1148-1156.	
	EA	G INGLE, T STEVENS, and C HOLT, SIROLIMUS: CONTINUING THE EVOLUTION OF TRANSPLANT IMMUNOSUPPRESSION, THE ANNALS OF PHARMACOTHERAPY 2000, 34:1044-1055.	
	EB	S MARX, A MARKS, BENCH TO BEDSIDE. THE DEVELOPMENT OF RAPAMYCIN AND ITS APPLICATION OF STENT RESTENOSIS, CIRCULATION 2001, 104:852-855.	
	EC	S.M. STEPKOWSKI and B.D. KAHAN, SYNERGISTIC ACTIVITY OF THE TRIPLE COMBINATION: CYCLOSPORINE, RAPAMYCIN, AND BREQUINAR, TRANSPLANTATION PROCEEDINGS 1993, 24:29-31.	
	ED	B KAHAN, M MURGIA, J SLATON, and K NAPOLI, POTENTIAL APPLICATIONS OF THERAPEUTIC DRUG MONITORING OF SIROLIMUS IMMUNOSUPPRESSION IN CLINICAL RENAL TRANSPLANTATION, THERAPEUTIC DRUG MONITORING 1995, 17:672-675.	
	EE	S SEHGAL, RAPAMUNE (RAPA, RAPAMYCIN, SIROLIMUS): MECHANISM OF ACTION IMMUNOSUPPRESSIVE EFFECT RESULTS FROM BLOCKADE OF SIGNAL TRANSDUCTION AND INHIBITION OF CELL CYCLE PROGRESSION, CLINICAL BIOCHEMISTRY 1998, 31:335-351.	
	EF	B KAHAN, J CHANG, S SEHGAL, PRECLINICAL EVALUATION OF A NEW POTENT IMMUNOSUPPRESSIVE AGENT, RAPAMYCIN, TRANSPLANTATION 1991, 52:185-191.	
	EG	O VILICKY, H ZOU, V MULLER, J LACHA, A SZABO and U HEEMANN, SDZ-RAD PREVENTS MANIFESTATION OF CHRONIC REJECTION IN RAT RENAL ALLOGRAFTS, TRANSPLANTATION 2000, 69:497-502.	
B	EH	K NAPOLI AND B KAHAN, HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY OF RAPAMYCIN, CLINICAL CHEMISTRY 1991, 37:294-295.	

Examiner Signature		Date Considered	9/30/04
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Application Number	
			Filing Date	
			First Named Inventor S. JAYARAMAN	
			Group Art Unit	
			Examiner Name	
Sheet 8 of 8			Attorney Docket Number 795-A03-004	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
B	EI	Henderson, D.J., I. Naya, R. V. Bundick, G.M. Smith and G. A. Schmidt. 1991. Comparison of the effects of FK-506, Cyclosporin-A, and rapamycin on IL-2 production. Immunology 73: 316.	
	EJ	Vathsala, A., T.C. Chou, B.D. Kahan. 1990. Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation. Transplantation 49: 463.	
	EK	Kahan B.D., S. Gibbons, N. Tejpal, S.M. Stepkowski, and T.C. Chou. 1991. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 51: 232.	
	EL	Tu Y, Stepkowski SM, Chou TC, Kahan BD. The synergistic effects of cyclosporine, sirolimus and brequinar on heart allograft survival in mice. Transplantation 1995; 59: 177.	
	EM	Martin DF, DeBarge LR, Nussenblatt RB, Chan CC, Roberge FG. Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis. J Immunol 1995; 154: 922.	
	EN	Yakimets WJ, Lakey JR, Yatscoff RW, et al. Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses: rapamycin efficacy is blood level related. Transplantation 1993; 56: 1293.	
	EO	Gregory CR, Huang X, Pratt RE, et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation. 1995; 59: 655-661.	
	EP	Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of cell cycle. Circulation, 1999; 99: 2164-2170.	
	EQ	REDDY, KR, Controlled-Release, Pegylation, Liposomal Formulations: New Mechanisms in the Delivery of Injectable Drugs, The Annals of Pharmacotherapy, Vol 34, pp 915-923, July/August 2000	
	ER	M. GUBA et al., Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor, Nature Medicine, Volume 8, February 2002, pp 128-135.	
ES	M. IURLARO et al., Antiangiogenesis by cyclosporine, Experimental Hematology, Volume 26, 1998, pp. 1215-1222.		

Examiner Signature		Date Considered	9/30/04
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ? ☐


PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete If Known	
<b>INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b> (use as many sheets as necessary)					
				Application Number	
				Filing Date	
				First Named Inventor S. Jayaramna	
				Group Art Unit	
				Examiner Name	
Sheet 3	of 8	Attorney Docket Number		795-A03-004	

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	BR	6,258,121		Yang et al.	07-10-2001	
	BS	6,273,913		Wright et al.	08-14-2001	
	BT	6,299,604		Ragheb	10-09-2001	
	BU	6,309,380		Larson	10-30-2001	
	BV	6,335,029		Kamath et al.	01-01-2002	
	BW	6,344,035		Chudzik et al.	02-05-2002	
	BX	6,364,903		Tseng et al.	04-02-2002	
	BY	6,368,658		Schwartz et al.	04-09-2002	
	BZ	6,379,382		Yang	04-30-2002	
	CA	6,455,518		Zenke et al	09-24-2002	
	CB	6,530,951		Bates	03-11-2003	
	CC	6,545,097		Pinchuk	04-08-2003	
	CD	6,585,764		Wright et al.	07-01-2003	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	DA		WO 98/55162	A2	Polybiomed Ltd.	12-10-1998		
	DB		WO 98/18468	A1	American Home Products	05-07-1998		
	DC		WO 98/07415	A2	Novartis AG	02-26-1996		
	DD		WO 96/04906	A1	Wellcome Foundation Ltd.	02-22-1996		

Examiner 	Date Considered 9/30/04
--	-------------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**